医薬品リファレンス
Erdafitinib
Erdafitinib is a medicine in the class oncology. It is used for bladder cancer.
- 薬効分類: Oncology
- 効能・効果: bladder cancer
最終更新日 出典: US FDA label
医療従事者向け・参照専用。このページは簡潔な要約であり、医学的助言ではなく、公式の添付文書や臨床判断に代わるものではありません。処方・調剤の前に必ず確認してください。
このページの臨床コンテンツは英語でのみ提供されています。
要点
- 薬効分類
- Oncology
- ATCコード
- L01EN01
- 一般的な剤形
- 錠剤
- 既知の相互作用
- 124 (重大: 22 · 中等度: 72 · 軽度: 30)
- 商品名
- 2
- 国・市場
- 2
何に使われるか
作用のしくみ
Kinase inhibitor that binds to and inhibits enzymatic activity of FGFR1, FGFR2, FGFR3 and FGFR4 (in vitro data); inhibits FGFR phosphorylation and signaling and decreases viability of cell lines with FGFR alterations.
成人の通常用量（添付文書の要約）
Locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 alterations: 8 mg orally once daily; increase to 9 mg once daily based on tolerability, including hyperphosphatemia, at 14 to 21 days; continue until disease progression or unacceptable toxicity
妊娠と授乳
- 妊娠
- Unsafe Can cause fetal harm: in rats it caused malformations and embryo-fetal death below human exposure. No human data. Verify pregnancy status; women, and men with female partners, use effective contraception during and for 1 month after.
- 授乳
- Unsafe No milk data. Because of possible serious reactions in the infant, do not breastfeed during treatment and for 1 month after the last dose.
報告されている副作用
- Increased phosphate
- Nail disorders
- Stomatitis
- Diarrhea
- Fatigue
- Dry mouth
禁忌
- None.
注意が必要な方
- Ocular disorders including CSR/RPED (22%) and dry eye; monthly eye exams for first 4 months then every 3 months, and urgently for visual symptoms; dry eye prophylaxis.
- Hyperphosphatemia and soft tissue mineralization; monitor phosphate, restrict dietary phosphate to 600–800 mg daily, consider phosphate binder if above 7.0 mg/dL.
- Embryo-fetal toxicity; verify pregnancy status and use effective contraception during treatment and for one month after last dose.
妊娠中または授乳中であること、腎臓や肝臓の病気、アレルギー、ほかに使用しているすべての薬やサプリメントについて、薬剤師または医師にお伝えください。
主な相互作用 (124)
- Amobarbital + Erdafitinib Major
- Apalutamide + Erdafitinib Major
- Carbamazepine + Erdafitinib Major
- Chloramphenicol + Erdafitinib Major
- Clarithromycin + Erdafitinib Major
- Colchicine + Erdafitinib Major
- Dabigatran etexilate + Erdafitinib Major
- Efavirenz + Erdafitinib Major
- Enzalutamide + Erdafitinib Major
- Erdafitinib + Fluconazole Major
Pro+会員向け
ページ全体を見る
アカウントを作成してPro+トライアルを始めると、Erdafitinibの完全なモノグラフ（用量、妊娠・授乳、副作用、警告、すべての相互作用）を表示できます。
- Dosing by age, kidney and liver function, and further dose lines
- Renal and hepatic dose adjustments
- How to give it
- Pharmacokinetics
- Patient counselling points
- Food interactions
WebでPro+を7日間無料でお試し。カード登録不要。
同じ分類のほかの薬剤
よくある質問
What is Erdafitinib used for?
Erdafitinib is a medicine in the class oncology. It is used for Bladder cancer.
What side effects have been reported with Erdafitinib?
Increased phosphate, Nail disorders, Stomatitis, Diarrhea, Fatigue, Dry mouth.
Can Erdafitinib be taken in pregnancy or while breastfeeding?
Pregnancy: Unsafe. Can cause fetal harm: in rats it caused malformations and embryo-fetal death below human exposure. No human data. Verify pregnancy status; women, and men with female partners, use effective contraception during and for 1 month after. Breastfeeding: Unsafe. No milk data. Because of possible serious reactions in the infant, do not breastfeed during treatment and for 1 month after the last dose.
What does Erdafitinib interact with?
MediHelp lists 124 known interactions for Erdafitinib. Major: 22 · Moderate: 72 · Minor: 30. The most serious include Amobarbital, Apalutamide, Carbamazepine.
完全なモノグラフ、用量、相互作用チェッカーはMediHelpアプリで
MediHelpアプリで、完全なリファレンスを開き、複数薬剤の相互作用をチェックし、用量ツールを利用できます。
